David Bentley on CSHL Meetings
  David Bentley     Biography    
Recorded: 14 May 2004

I don’t actually know much about Cold Spring Harbor—the laboratory as an institution. I really only know them as a center for the meetings. And in that sense this place is unique. I think it’s a tremendous tradition, doubtless built up with a great deal of effort and input from Jim Watson and many others—but a very important and probably a rather visionary development for the laboratories. Also, of course, beautiful surroundings, which really are very stimulating, I think. There is a great hospitality surrounding this place, which is not shared by other places. And of course you don’t get this when you have a conference in a hotel. You get the hospitality of a hotel, but you don’t get the surrounding, the ambiance, the sheer relaxed academic atmosphere, which pervades the grounds and the conferences, which are here. Many new things are discussed and discovered as a result of the informal contact, which this place stimulates

David Bentley, molecular biologist and geneticist, is currently Vice President and Chief Scientist of DNA Sequencing at Illumina, Inc., a commercial developer of genetic analysis tools and systems.

Educated at the University of Cambridge (M.A. in biochemistry) and the University of Oxford (Ph. D.), Dr. Bentley was a postdoctoral fellow, lecturer, and senior lecturer at Guy's and St. Thomas's Hospital in London from 1991 to 1993 where he studied mutations that cause genetic diseases, and a Senior Lecturer in the Division of Medical & Molecular Genetics at the University of London.

In 1993 he was brought to Sanger Centre (now known as Wellcome Trust Sanger Institute) as a founding member and head of human genetics by his mentor, John Sulston. Dr. Bentley led Sanger in their major contributions to the Human Genome Project, The Single Nucleotide Polymorphisms (SNP) Consortium, and the International Haplotype Mapping (HapMap) Project. Dr. Bentley left Wellcome in 1985 to join commercial sequencer, Solexa, Inc., as Chief Scientist where he was responsible for the Company’s DNA sequencing applications development and projects. Solexa was acquired by Illumina in 2007.